益脾养肝方联合TACE、3DCRT治疗原发性肝癌疗效观察

发布时间：2018-05-03 14:05

本文选题：益脾养肝方 + 原发性肝癌　；参考：《辽宁中医杂志》2017年05期

【摘要】：目的:观察和评价益脾养肝方联合TACE和3DCRT治疗原发性肝癌的临床疗效。方法:51例原发性肝癌患者随机分为治疗组(26例),给予中药益脾养肝方联合TACE及3DCRT治疗;对照组(25例),给予TACE和3DCRT治疗。两组疗程35~42 d(根据3DCRT治疗时间而变化)。观察和比较两组病例在治疗前后中医证候、实体瘤大小、细胞免疫功能、肝功能、生存率等方面的相关指标并进行统计分析。结果:经治疗后,治疗组中医疗效总有效率88.0%,对照组中医疗效总有效率32.0%,两组比较有显著性差异(P0.05)。治疗组在中医证候改善,CD3+、CD3+CD4+变化,降低ALT、AST等方面优于对照组,差异有统计学意义(P0.05)。治疗组在实体瘤大小改变、生存率等方面均优于对照组,但差异无统计学意义(P0.05㖞。结论:益脾养肝方联合TACE和3DCRT治疗原发性肝癌,可以明显改善患者临床症状、改善生化指标、提高患者生活质量,且安全可靠。
[Abstract]:Objective: to observe and evaluate the clinical effect of Yipi Yanggan recipe combined with TACE and 3DCRT in the treatment of primary liver cancer. Methods Fifty-one patients with primary liver cancer were randomly divided into treatment group (n = 26) and control group (n = 25) treated with TACE and 3DCRT. The course of treatment in both groups was 35 days and 42 days (according to the time of 3DCRT treatment). The indexes of TCM syndromes, tumor size, cellular immune function, liver function and survival rate before and after treatment were observed and compared. Results: after treatment, the total effective rate of TCM was 88.0 in the treatment group and 32.0 in the control group. The difference between the two groups was significant (P 0.05). The treatment group was superior to the control group in improving the changes of CD3 + CD3 CD4 and decreasing alt in TCM syndromes. The difference was statistically significant (P 0.05). The size of solid tumor and survival rate in the treatment group were better than those in the control group, but the difference was not statistically significant (P 0.05). Conclusion: Yipi Yanggan recipe combined with TACE and 3DCRT can obviously improve the clinical symptoms, improve biochemical indexes, improve the quality of life of patients, and is safe and reliable.
【作者单位】：陕西中医药大学附属医院;
【基金】：国家自然科学基金(81603612) 陕西省科技厅(2012SF2-11,2014K11-02-04-06,2016SF-234) 陕西省中医药管理局(15-JC009) 北京医学奖励基金会课题(YJHYXKYJJ-276)
【分类号】：R735.7

【相似文献】